Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection after CDK4/6 inhibitor progression in advanced ER-positive breast cancer.
Back
How Real-World Evidence Is Shaping Treatment Decisions in ER+ Breast Cancer
Hope S. Rugo, MD, and Seth Wander, MD, PhD, examine how real-world evidence is increasingly informing treatment decisions in advanced ER-positive breast cancer.
How Real-World Evidence Is Shaping Treatment Decisions in ER+ Breast Cancer
Episodes
All
All
Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.
Explore the impact of elacestrant on ESR1-mutated breast cancer, revealing real-world data insights and genomic factors influencing treatment outcomes.
EP. 4: Additional Real-World Time to Next Treatment Outcomes With Elacestrant in ESR1+ Breast Cancer
Researchers analyze real-world data on ESR1-mutated breast cancer treatments, revealing promising outcomes and insights for patient care strategies.
EP. 5: Ways Oral SERDs and Targeted Therapies Could Continue to Reshape ER+ Breast Cancer Management
Experts discuss the implications of the SERENA-6 trial, highlighting the potential benefits of early oral SERD deployment in breast cancer treatment.
Experts discuss the future of breast cancer treatment, emphasizing personalized approaches and the potential of new oral therapies to improve outcomes.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
4
NMA Associates MRD-Negative CR With PFS in Earlier-Line R/R Myeloma
5